MedPath
Found 1 clinical trials|View Analysis
Sort by:

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Phase 1
Active, not recruiting
Conditions
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2014-11-14
Last Posted Date
2024-11-05
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
200
Registration Number
NCT02290951
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇫🇷

Institut Gustave Roussy, Villejuif, ÃŽle-de-France, France

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 19 locations
© Copyright 2025. All Rights Reserved by MedPath